About the Journal

About

Cancer Biome and Targeted Therapy (CBTT) publishes peer-reviewed, interdisciplinary research and reviews focused on the tumor microenvironment, microbial influences, immune dynamics, and mechanisms of resistance to cancer therapies.

Aims and Scope

Cancer Biome and Targeted Therapy is a peer-reviewed, open-access journal publishing high-quality, interdisciplinary research at the intersection of tumor biology, immunology, microbiology, and precision oncology. The journal advances understanding of the cancer biome, the complex biological and microbial ecosystem surrounding tumor cells, and its impact on cancer progression, immune modulation, therapeutic resistance, and clinical outcomes.

Cancer Biome and Targeted Therapy welcomes original research, reviews, and translational studies addressing key areas, including:

  • Oncology: Molecular and translational cancer research, tumor biology, disease progression, and therapeutic response.
  • Immunology: Immune tumor microenvironment and host–tumor interactions.
  • Microbiology: Microbial ecosystems, including bacterial, fungal, viral, and parasitic components, and their influence on the tumor niche.
  • Biochemistry & Molecular Biology: Molecular cancer mechanisms, signaling, biomarkers, diagnostics, and therapeutic targets.
  • Pharmacology and therapeutics: Resistance mechanisms and the development of precision and targeted therapies.
  • Molecular Medicine: Molecular and genetic mechanisms underlying cancer initiation, progression, and therapy response.

The journal supports research bridging basic science and clinical application to foster innovation in cancer diagnostics, prognostics, and treatment. View our Editorial Team

Cancer Biome and Targeted Therapy upholds the highest standards of ethical open-access publishing, adhering to DOAJ and COPE guidelines while maintaining full editorial independence. Articles are assigned DOIs, and authors are encouraged to use ORCID for persistent researcher identification. Metadata are regularly updated to enhance discoverability and indexing.

Mission Statement

Cancer Biome and Targeted Therapy is committed to advancing a systems-level understanding of cancer by exploring the biological, immunological, microbial, and therapeutic dimensions of the tumor environment. Our mission is to provide an open-access platform for high-quality, peer-reviewed research that uncovers how the complex interplay between tumors and their surrounding ecosystems influences disease behavior, therapeutic resistance, and clinical outcomes.

By integrating insights from immunology, microbiology, pharmacology, and computational biology, Cancer Biome and Targeted Therapy aims to catalyze innovation in cancer prevention, diagnosis, and precision treatment. We are dedicated to supporting interdisciplinary collaboration, global scientific exchange, and the responsible dissemination of knowledge that ultimately improves patient care.

Open Access

Under the open access model, Cancer Biome and Targeted Therapy does not apply embargoes or subscription restrictions. All articles are made freely accessible immediately upon publication, providing readers with instant, unrestricted access to the content. All articles are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). https://creativecommons.org/licenses/by/4.0/.

As the authors of articles published in Cancer Biome and Targeted Therapy, you retain the copyright to your work. By publishing with us, you allow any third party the right to use, reproduce, and distribute your article in perpetuity, given that the terms of the applicable open-access license are followed.

Open Journal System and Archival System

Cancer Biome and Targeted Therapy is hosted on the Open Journal Systems (OJS) platform, developed and maintained by the Public Knowledge Project (PKP) with daily backups, digital preservation, and archiving on the PKP Preservation Network (PKP PN) using the LOCKSS Program. Once an ISSN has been attributed, Cancer Biome and Targeted Therapy will, in addition to PKP PN, participate in the LOCKSS program to ensure long-term digital preservation.

Although the platform complies with relevant privacy and data protection regulations, including the British Columbia Freedom of Information and Protection of Privacy Act (FIPPA) and the European Union’s General Data Protection Regulation (GDPR), the journal does not control or guarantee the performance, availability, or security of the platform’s infrastructure. By using this website, users acknowledge and agree that the journal and its publisher shall not be held responsible for any damages or losses arising from platform-related failures or from external data-handling processes managed by PKP or its hosting providers.

Metadata Exposure and Repository Interoperability

In addition to digital preservation, Cancer Biome and Targeted Therapy supports standardized metadata dissemination through the Open Archives Initiative Protocol for Metadata Harvesting (OAI-PMH). Article-level metadata are made available for harvesting by libraries, institutional repositories, and indexing services, facilitating discovery, citation, and long-term accessibility of published content.

Publishing Frequency

Cancer Biome and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes four regular issues per year, scheduled for February, May, August, and November.

The journal operates an Early View (online-first) publication model. Articles are published online individually once they have completed peer review and all editorial and production requirements. Early View articles are fully accessible, citable, and indexed upon online publication.

Formal issue compilation is performed on a quarterly basis. Once an issue is completed, Early View articles are assigned to a specific volume and issue. The ordering of articles within an issue is determined by editorial structure and thematic organization rather than the chronological order of online publication.

Language

English

Article Processing Charge (APC)

Cancer Biome and Targeted Therapy does not charge any publication fees, and all articles are freely accessible to readers.

Self-Archiving Policy (For Accepted Manuscripts):

Authors are permitted and encouraged to post the accepted version (postprint) of their manuscript, after peer review but before final typesetting, in personal repositories, institutional archives, or recognized preprint servers. This policy applies to the accepted manuscript version and does not restrict the sharing of links to the final published version of record.

To preserve the integrity of the published record, authors should:

  • Clearly label the version as "Accepted Manuscript."
  • Include the DOI and citation to the final published version once available
  • Do not share the formatted publisher PDF without prior permission

This policy supports author visibility, compliance with funder requirements, and the broader goals of open science.

About the Publisher 

Publisher: © GCINC Press (Imprint of Global Consulting Inc.) is an independent academic publisher based in the United States. GCINC Press is the publishing division of Global Consulting Inc., the legal entity responsible for the journal’s management and operations. GCINC Press publishes Cancer Biome and Targeted Therapy and is committed to high-quality, peer-reviewed, open-access publishing.

Publisher Address: Global Consulting Inc (GCINC Press), 522 W Riverside Ave Ste N., Spokane, WA 99201, USA.

Contact Email: submissions@cancerbiometherapy.com

Last updated: November 2025